Abzu vs Ochre Bio

<p>Abzu is a biotechnology software platform that leverages artificial intelligence to develop advanced RNA therapies such as siRNAs, ASOs, and anti-miRs for major medical needs. It integrates deep RNA biology knowledge with AI-driven design and drug development expertise, enabling you to explore and prioritize vast RNA sequence variants computationally. This reduces experimental costs, shortens candidate selection time, and improves overall drug design efficiency.</p> <p>The platform also supports targeted RNA delivery by developing programmable aptamers for cell-specific uptake, creating a modular system for precision beyond traditional liver-focused delivery. Abzu serves biotech researchers and pharmaceutical teams aiming to innovate RNA drug development, offering case studies and AI models that enhance therapeutic design safety and efficacy. While currently fundraising, Abzu emphasizes explainable AI to boost pharma trust and streamline workflows.</p>

<p>Ochre Bio is a cutting-edge platform that combines AI with large-scale human liver data to accelerate drug discovery specifically for chronic liver diseases. It enables you to explore causal disease mechanisms, validate targets in human tissue, and develop RNA therapies in-house, significantly reducing R&amp;D timelines. The platform targets the pharmaceutical industry and research organizations aiming to find effective treatments beyond liver transplants.</p> <p>With investments in proprietary datasets and integrated gene atlases, Ochre Bio supports discovery, validation, and clinical development pipelines. You benefit from access to mechanistic insights, RNA therapeutic development, and partnerships with leading companies like GSK. This platform aims to revolutionize liver disease treatment by making drug development faster and more precise.</p>